Changes in viral loads of lamivudine-resistant mutants during entecavir therapy
Aim: Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus an...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2008-02, Vol.38 (2), p.132-140 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 140 |
|---|---|
| container_issue | 2 |
| container_start_page | 132 |
| container_title | Hepatology research |
| container_volume | 38 |
| creator | Suzuki, Fumitaka Suzuki, Yoshiyuki Akuta, Norio Yatsuji, Hiromi Sezaki, Hitomi Arase, Yasuji Kawamura, Yusuke Hosaka, Tetsuya Kobayashi, Masahiro Ikeda, Kenji Kobayashi, Mariko Watahiki, Sachiyo Kumada, Hiromitsu |
| description | Aim: Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus and determined changes in viral precore and core promoter mutants.
Methods: Nineteen patients were treated in randomized, double‐blind phase II clinical trials of entecavir at 0.5 or 1.0 mg for breakthrough hepatitis due to lamivudine‐resistant virus. Viral changes in YMDD mutants (rtM204I, rtM204V), amino acid changes in the polymerase reverse transcriptase region and precore/core promoter mutations at 52 weeks were determined in 18 patients.
Results: Changes in viral loads of rtM204I and rtM204V were similar. No differences in load changes were seen betweenthe 0.5 and 1.0 mg groups. However, load changes for rtM204I alone were greater than those for the rtM204I + rtM204V mixed‐type (P = 0.042, at both 40 and 52 weeks). Load changes in rtM204I and rtM204V with G1896A tended to be greater than those without. Moreover, G1896A was replaced by wild‐type virus in two patients at 52 weeks.
Conclusion: RtM204I only or the existence of precore mutation was more sensitive to entecavir therapy against lamivudine‐resistant virus. |
| doi_str_mv | 10.1111/j.1872-034X.2007.00144.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734244876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734244876</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5254-cab7be25c2f60dac65e1b1029418568e155a8b040a1a14fc024aa07422ee46533</originalsourceid><addsrcrecordid>eNqNkMtv1DAQhy0Eog_4F5BvnBL8dnrgAKu-pC1tEa-bNUkmrZc8Fjtpd__7OuyqXJnLjDS_b2x9hFDOcp7qwyrnhRUZk-pXLhizOWNcqXzzghw-L16mWRYmM1KZA3IU4yqFLBPqNTngVlt5ovkhuV7cQ3-HkfqePvgALW0HqCMdGtpC5x-m2veYBYw-jtCPtJvmFmk9Bd_fUexHrCCBdLzHAOvtG_KqgTbi230_Jt_PTr8tLrLl9fnl4tMyq7TQKqugtCUKXYnGsBoqo5GXnIkTxQttCuRaQ1EyxYADV02Vvg3ArBICURkt5TF5v7u7DsOfCePoOh8rbFvocZiis1IJpQprUrLYJaswxBiwcevgOwhbx5mbbbqVm6W5WZqbbbq_Nt0moe_2j0xlh_U_cK8vBT7uAo--xe1_H3YXpzdf05T4bMcnu7h55iH8dsZKq93PL-eOX50VP65uP7ulfAJ1dpMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>734244876</pqid></control><display><type>article</type><title>Changes in viral loads of lamivudine-resistant mutants during entecavir therapy</title><source>Access via Wiley Online Library</source><creator>Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Arase, Yasuji ; Kawamura, Yusuke ; Hosaka, Tetsuya ; Kobayashi, Masahiro ; Ikeda, Kenji ; Kobayashi, Mariko ; Watahiki, Sachiyo ; Kumada, Hiromitsu</creator><creatorcontrib>Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Arase, Yasuji ; Kawamura, Yusuke ; Hosaka, Tetsuya ; Kobayashi, Masahiro ; Ikeda, Kenji ; Kobayashi, Mariko ; Watahiki, Sachiyo ; Kumada, Hiromitsu</creatorcontrib><description>Aim: Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus and determined changes in viral precore and core promoter mutants.
Methods: Nineteen patients were treated in randomized, double‐blind phase II clinical trials of entecavir at 0.5 or 1.0 mg for breakthrough hepatitis due to lamivudine‐resistant virus. Viral changes in YMDD mutants (rtM204I, rtM204V), amino acid changes in the polymerase reverse transcriptase region and precore/core promoter mutations at 52 weeks were determined in 18 patients.
Results: Changes in viral loads of rtM204I and rtM204V were similar. No differences in load changes were seen betweenthe 0.5 and 1.0 mg groups. However, load changes for rtM204I alone were greater than those for the rtM204I + rtM204V mixed‐type (P = 0.042, at both 40 and 52 weeks). Load changes in rtM204I and rtM204V with G1896A tended to be greater than those without. Moreover, G1896A was replaced by wild‐type virus in two patients at 52 weeks.
Conclusion: RtM204I only or the existence of precore mutation was more sensitive to entecavir therapy against lamivudine‐resistant virus.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/j.1872-034X.2007.00144.x</identifier><identifier>PMID: 17573951</identifier><language>eng</language><publisher>Melbourne, Australia: Blackwell Publishing Asia</publisher><subject>entecavir ; hepatitis B virus ; lamivudine ; precore ; YMDD mutant</subject><ispartof>Hepatology research, 2008-02, Vol.38 (2), p.132-140</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5254-cab7be25c2f60dac65e1b1029418568e155a8b040a1a14fc024aa07422ee46533</citedby><cites>FETCH-LOGICAL-c5254-cab7be25c2f60dac65e1b1029418568e155a8b040a1a14fc024aa07422ee46533</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1872-034X.2007.00144.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1872-034X.2007.00144.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17573951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Yatsuji, Hiromi</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kobayashi, Mariko</creatorcontrib><creatorcontrib>Watahiki, Sachiyo</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><title>Changes in viral loads of lamivudine-resistant mutants during entecavir therapy</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aim: Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus and determined changes in viral precore and core promoter mutants.
Methods: Nineteen patients were treated in randomized, double‐blind phase II clinical trials of entecavir at 0.5 or 1.0 mg for breakthrough hepatitis due to lamivudine‐resistant virus. Viral changes in YMDD mutants (rtM204I, rtM204V), amino acid changes in the polymerase reverse transcriptase region and precore/core promoter mutations at 52 weeks were determined in 18 patients.
Results: Changes in viral loads of rtM204I and rtM204V were similar. No differences in load changes were seen betweenthe 0.5 and 1.0 mg groups. However, load changes for rtM204I alone were greater than those for the rtM204I + rtM204V mixed‐type (P = 0.042, at both 40 and 52 weeks). Load changes in rtM204I and rtM204V with G1896A tended to be greater than those without. Moreover, G1896A was replaced by wild‐type virus in two patients at 52 weeks.
Conclusion: RtM204I only or the existence of precore mutation was more sensitive to entecavir therapy against lamivudine‐resistant virus.</description><subject>entecavir</subject><subject>hepatitis B virus</subject><subject>lamivudine</subject><subject>precore</subject><subject>YMDD mutant</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNqNkMtv1DAQhy0Eog_4F5BvnBL8dnrgAKu-pC1tEa-bNUkmrZc8Fjtpd__7OuyqXJnLjDS_b2x9hFDOcp7qwyrnhRUZk-pXLhizOWNcqXzzghw-L16mWRYmM1KZA3IU4yqFLBPqNTngVlt5ovkhuV7cQ3-HkfqePvgALW0HqCMdGtpC5x-m2veYBYw-jtCPtJvmFmk9Bd_fUexHrCCBdLzHAOvtG_KqgTbi230_Jt_PTr8tLrLl9fnl4tMyq7TQKqugtCUKXYnGsBoqo5GXnIkTxQttCuRaQ1EyxYADV02Vvg3ArBICURkt5TF5v7u7DsOfCePoOh8rbFvocZiis1IJpQprUrLYJaswxBiwcevgOwhbx5mbbbqVm6W5WZqbbbq_Nt0moe_2j0xlh_U_cK8vBT7uAo--xe1_H3YXpzdf05T4bMcnu7h55iH8dsZKq93PL-eOX50VP65uP7ulfAJ1dpMM</recordid><startdate>200802</startdate><enddate>200802</enddate><creator>Suzuki, Fumitaka</creator><creator>Suzuki, Yoshiyuki</creator><creator>Akuta, Norio</creator><creator>Yatsuji, Hiromi</creator><creator>Sezaki, Hitomi</creator><creator>Arase, Yasuji</creator><creator>Kawamura, Yusuke</creator><creator>Hosaka, Tetsuya</creator><creator>Kobayashi, Masahiro</creator><creator>Ikeda, Kenji</creator><creator>Kobayashi, Mariko</creator><creator>Watahiki, Sachiyo</creator><creator>Kumada, Hiromitsu</creator><general>Blackwell Publishing Asia</general><scope>BSCLL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200802</creationdate><title>Changes in viral loads of lamivudine-resistant mutants during entecavir therapy</title><author>Suzuki, Fumitaka ; Suzuki, Yoshiyuki ; Akuta, Norio ; Yatsuji, Hiromi ; Sezaki, Hitomi ; Arase, Yasuji ; Kawamura, Yusuke ; Hosaka, Tetsuya ; Kobayashi, Masahiro ; Ikeda, Kenji ; Kobayashi, Mariko ; Watahiki, Sachiyo ; Kumada, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5254-cab7be25c2f60dac65e1b1029418568e155a8b040a1a14fc024aa07422ee46533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>entecavir</topic><topic>hepatitis B virus</topic><topic>lamivudine</topic><topic>precore</topic><topic>YMDD mutant</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Fumitaka</creatorcontrib><creatorcontrib>Suzuki, Yoshiyuki</creatorcontrib><creatorcontrib>Akuta, Norio</creatorcontrib><creatorcontrib>Yatsuji, Hiromi</creatorcontrib><creatorcontrib>Sezaki, Hitomi</creatorcontrib><creatorcontrib>Arase, Yasuji</creatorcontrib><creatorcontrib>Kawamura, Yusuke</creatorcontrib><creatorcontrib>Hosaka, Tetsuya</creatorcontrib><creatorcontrib>Kobayashi, Masahiro</creatorcontrib><creatorcontrib>Ikeda, Kenji</creatorcontrib><creatorcontrib>Kobayashi, Mariko</creatorcontrib><creatorcontrib>Watahiki, Sachiyo</creatorcontrib><creatorcontrib>Kumada, Hiromitsu</creatorcontrib><collection>Istex</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Fumitaka</au><au>Suzuki, Yoshiyuki</au><au>Akuta, Norio</au><au>Yatsuji, Hiromi</au><au>Sezaki, Hitomi</au><au>Arase, Yasuji</au><au>Kawamura, Yusuke</au><au>Hosaka, Tetsuya</au><au>Kobayashi, Masahiro</au><au>Ikeda, Kenji</au><au>Kobayashi, Mariko</au><au>Watahiki, Sachiyo</au><au>Kumada, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in viral loads of lamivudine-resistant mutants during entecavir therapy</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2008-02</date><risdate>2008</risdate><volume>38</volume><issue>2</issue><spage>132</spage><epage>140</epage><pages>132-140</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aim: Entecavir therapy is effective against lamivudine‐resistant virus in patients with hepatitis B virus infection. We investigated viral load changes of YMDD mutant virus (rtM204I [YIDD sequence], rtM204V [YVDD]) in serial serum samples during entecavir treatment for lamivudine‐resistant virus and determined changes in viral precore and core promoter mutants.
Methods: Nineteen patients were treated in randomized, double‐blind phase II clinical trials of entecavir at 0.5 or 1.0 mg for breakthrough hepatitis due to lamivudine‐resistant virus. Viral changes in YMDD mutants (rtM204I, rtM204V), amino acid changes in the polymerase reverse transcriptase region and precore/core promoter mutations at 52 weeks were determined in 18 patients.
Results: Changes in viral loads of rtM204I and rtM204V were similar. No differences in load changes were seen betweenthe 0.5 and 1.0 mg groups. However, load changes for rtM204I alone were greater than those for the rtM204I + rtM204V mixed‐type (P = 0.042, at both 40 and 52 weeks). Load changes in rtM204I and rtM204V with G1896A tended to be greater than those without. Moreover, G1896A was replaced by wild‐type virus in two patients at 52 weeks.
Conclusion: RtM204I only or the existence of precore mutation was more sensitive to entecavir therapy against lamivudine‐resistant virus.</abstract><cop>Melbourne, Australia</cop><pub>Blackwell Publishing Asia</pub><pmid>17573951</pmid><doi>10.1111/j.1872-034X.2007.00144.x</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2008-02, Vol.38 (2), p.132-140 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734244876 |
| source | Access via Wiley Online Library |
| subjects | entecavir hepatitis B virus lamivudine precore YMDD mutant |
| title | Changes in viral loads of lamivudine-resistant mutants during entecavir therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T09%3A28%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20viral%20loads%20of%20lamivudine-resistant%20mutants%20during%20entecavir%20therapy&rft.jtitle=Hepatology%20research&rft.au=Suzuki,%20Fumitaka&rft.date=2008-02&rft.volume=38&rft.issue=2&rft.spage=132&rft.epage=140&rft.pages=132-140&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/j.1872-034X.2007.00144.x&rft_dat=%3Cproquest_cross%3E734244876%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=734244876&rft_id=info:pmid/17573951&rfr_iscdi=true |